58 results about "Pandemic" patented technology

The invention relates to a sauna heater and a sauna+bio-danarium combination heater. An evaporator-batch column 10 for liquid 30 is arranged in the oven. The advantageous invention is suitable for wall and floor models, as well as for "stone column tower" oven models, etc., also for taller and larger oven models, with the novel "Löyly tub bowl" 13 for energy-saving infusions and Löyly infusions in its variations and bath forms. This energy-saving new development with the "multi-path air control" and the "anti-virus corona pandemic" block system 26 is also perfectly suited against infectious aerosols and mutants and also in splash water at ground level. With current technology, the sauna and sauna+bio-danarium combination can be operated via an "app" from a smartphone or tablet, also via touchscreen. Experience and development from several innovations over 55 years in the sauna+ sauna+danarium wellness area.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

RFID-based operations management systems and methods are provided herein, particularly RFID based Kanban systems. Such system can realize increased efficiencies, improved visibility of inventory throughout the workflow and improved response to variations in demand. RFID based solutions can automatically transact consumption of Kanban inventory in real-time and trigger replenishment signals to warehouses automatically, resulting in increased Kanban inventory accuracy and lower manual efforts for replenishment and consumption posting. This approach can interface with existing operational management software (e.g. ERP systems, such as SAP) seamlessly integrating with product manufacturing workflows. Such systems are uniquely applicable to manufacture of biological testing kits, where demands fluctuate considerably in response to crises, disasters, epidemics and pandemics.

The nose mask is intended to be used during an airborne pandemic. The nose mask is a single triangle / cone shaped that covers only the nose, that comes with two ear elastic bands or a single head elastic band for support. The nose mask is designed to be disposable with a filter for better protection and to minimize the passage of aerosols, fluids and airborne pathogen agents or to be made with washable material allowing users to re-use it.

Infectious diseases remain a problem worldwide. The sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has infected over 640 million people worldwide. SARS-CoV-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein allow SARS-CoV-2 variants to evade neutralizing monoclonal antibodies generated from previous infections or by vaccination with SARS-CoV-2. The present invention provides antibodies that bind to the SARS-CoV-2 spike (S) protein. The present invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods that use the aforementioned antibodies that bind to the SARS-CoV-2 spike (S) protein.

Organizations are struggling to ensure business continuity without compromising on delivery excellence in the face of pandemic related uncertainties which exists along multiple dimensions effected by authorities. This uncertainty plays out in a non-uniform manner thus leading to highly heterogeneous evolution of pandemic. Present disclosure provides digital twin based systems and methods for business continuity plan and safe return to workplace wherein a simulation-based data-driven evidence-backed approach is implemented that captures details pertaining to virus, individualistic characteristics of employees and their dependents, offices, locations of the employees and offices, and various pandemic control measures that are in effect and need to be explored using a hybrid modelling and simulation approach that combines fine-grained actor / agent model and coarse-grained stock-and-flow model. The present disclosure further leverages past macro-level data pertaining to pandemic evolution of relevant cities, states, and countries to make available information amenable for collective analysis and infection prediction.

A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus, as well as the DNA fragments and their mRNA transcriptions, can then be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate production methodology using computationally reducible fragments removed from Super Organisms either collectively or individually; as well as the DNA fragments themselves and the mRNA transcripts of those fragments.

The present application relates to the field of microbial detection technology, and in particular to a primer and probe for detecting Vibrio parahaemolyticus, as well as a kit and application. The present application provides the use of a reagent for detecting the CG3 gene in the preparation of a kit for detecting Vibrio parahaemolyticus; wherein the nucleotide sequence of the CG3 gene is shown in SEQ ID NO.1. The present application discovered that there is a specific sequence, namely the CG3 gene, in the pandemic clone group CG3 of Vibrio parahaemolyticus. Therefore, the reagent for detecting the CG3 gene provides a basis for rapidly identifying the pandemic clone group CG3 of Vibrio parahaemolyticus and establishing a fluorescent PCR technology for rapidly identifying the pandemic clone group CG3 of Vibrio parahaemolyticus. This provides a reference for tracing and investigating the source of high-risk factors of the pandemic clone group CG3 of Vibrio parahaemolyticus, which is of great significance for further carrying out the work of preventing and controlling the population infected by Vibrio parahaemolyticus.

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS-Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.

The application discloses an energy supply planning method and device under an emergency, a storage medium and a system. By considering the influence of an emergency such as a disease pandemic, combining the different influences of different regions under external events, and building an energy supply cost optimization model considering the impact of events such as pandemics, the energy supply cost is reasonably optimized. The energy supply planning management method, device, storage medium and system under the emergency improve the energy supply planning efficiency and accuracy under the emergency.

The present invention relates to an ESP decision optimization system for epidemiological modeling. ESP based modeling approach is used to predict how non-pharmaceutical interventions (NPIs) affect a given pandemic, and then automatically discover effective NPI strategies as control measures. The ESP decision optimization system comprises of a data-driven predictor, a supervised machine learning model, trained with historical data on how given actions in given contexts led to specific outcomes. The Predictor is then used as a surrogate in order to evolve prescriptor, i.e. neural networks that implement decision policies (i.e. NPIs) resulting in best possible outcomes. Using the data-driven LSTM model as the Predictor, a Prescriptor is evolved in a multi-objective setting to minimize the pandemic impact.

The invention relates to a new infectious disease multi-stage strategy optimization method for balancing health and economy, and the method comprises the steps: representing population flow on different land utilization through introducing noctilucence for land utilization; a land utilization perception infectious disease model is used for simulating and evaluating single or combined management and control measures of different land parcels based on a health dimension, and an input-output economic disaster influence model is used for simulating and evaluating single or combined management and control measures of different land parcels based on an economic dimension. And based on two dimensions of target optimization health and economy of different stages of the new infectious disease, obtaining multi-stage optimal countermeasures. Therefore, the problems that existing direct population flow data are missing, so that simulation is difficult, and health and economic loss are difficult to balance in different stages of infectious disease pandemic are solved.

The present disclosure relates to a novel coronavirus SARS-CoV-2 mutant vaccine and its application, the vaccine comprising a fusion protein comprising: (1) interferon or a functional fragment thereof; (2) novel coronavirus SARS-CoV-2 or a functional fragment thereof; and (3) an immunoglobulin Fc region. The mutant vaccine disclosed herein has long-lasting efficacy, is amenable to industrial production, has activity comparable to that of conventional IFN, has higher immunogenicity and neutralizing antibody titers, and can increase defense against mutant strains. It can be used as a new generation of mutant vaccine drugs to combat the spread of the COVID-19 pandemic.

Infectious diseases have been sources of large-scale epidemics and pandemics resulting in millions of casualties worldwide. Detection of these biological agents normally involves several lab processes including sample preparation, nucleic acid separation and amplification, and diagnostic analysis. These steps, either performed manually or automated by high-throughput machinery, are tedious, expensive, and highly susceptible to cross-contamination. The present system is an integrated lab-on-a-device designed, developed, and tested in compatibility with a mechanical fixture for sample-to-answer biological analysis of infectious diseases.

This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product. The double-encapsulated mRNA vaccine product is stable at room temperature and can be administered in a single shot to humans.

An object of the system according to the embodiment is to perform quick and effective prediction and measures for preventing occurrence of a new pandemic.SOLUTION: A system includes a variant prediction unit, a vaccine design unit, a data collection unit, and a preventive measure proposal unit. The variant prediction unit predicts a variant of a virus. The vaccine design unit designs a vaccine based on the structure information of the variant predicted by the variant prediction unit. The data collection unit collects and analyzes disease data collected from around the world in real time. A preventive measure proposal part proposes preventive measures in cooperation with an international health organization on the basis of the data collected and analyzed by the data collection part.SELECTED DRAWING: Figure 1

The present invention discloses a neutralizing monoclonal antibody against the HA protein of the Eurasian avian and Pdm / 09 evolutionary lineage H1 subtype swine influenza virus and its application. The monoclonal antibody is named 5F3 and the deposit number is CCTCC NO: C2022145. The monoclonal antibody targets the HA protein and can not only specifically recognize Eurasian avian H1N1 subtype swine influenza viruses of various genotypes including G4, but also has good reactivity to the 2009 pandemic (Pdm / 09) H1N1 subtype swine influenza virus, and can bind to human and avian H1N1 subtype influenza viruses, showing broad-spectrum action characteristics against H1 subtype influenza viruses. The monoclonal antibody of the present invention has been shown to have strong neutralizing activity through chicken embryo neutralization tests and mouse preventive protection tests, and is expected to be used in the diagnosis and prevention of diseases of pigs caused by H1N1 subtype swine influenza viruses and possible human infections.

The present invention relates to a folding, forming and flattening device and a mask production machine. The folding, forming and flattening device comprises a feeding component (100) for feeding a continuous sheet, a pre-folding, forming component (200) for forming an initial sinusoidal sheet from the continuous sheet, a primary folding, forming component (300) for forming a primary sinusoidal sheet from the initial sinusoidal sheet, a folding, forming and flattening component (400) for forming a mask sheet with folds from the primary sinusoidal sheet, and a receiving component (600) for receiving the mask sheet with folds. The present invention provides a better method for producing masks that are more cost-effective, less contaminated by particles, and better in cleanliness for use by the public during the current COVID-19 pandemic faced by the global population.

Increasingly, infectious diseases due to viruses, bacteria, fungi and other contact-transmissible microorganisms, droplets and / or aerosols, are acquiring greater importance due to globalisation and the ease of dissemination between very distant countries. A characteristic example is the Influenza A pandemic in 2009 and the SARS pandemics due to the SARS-Cov virus in 2003 and the COVID-19 pandemic due to the SARS-CoV-2 virus in 2020. To combat infections that may occur by contact, or by aerosolised drops (including those surfaces contaminated with infectious agents), a wider palette of antimicrobials and virucides is required. The present invention resolves this problem for viral infections with the use of a low toxicity surfactant from the group of trimethylammonium methyl sulfates.

One problem to be addressed by the present invention is to provide a drug which is capable of suppressing the proliferation of SARS-CoV-2 with high efficiency. Another problem to be addressed by the present invention is to provide a drug which exhibits an inhibitory effect on a wide range of coronaviruses and thereby can immediately respond to the pandemic of unknown SARS-CoV-2 mutants and new types of coronaviruses which could happen in the future.　Provided is an oligonucleotide or a pharmaceutically acceptable salt thereof, wherein: the oligonucleotide comprises an oligonucleotide that is composed of 17-30 nucleotides and comprises a nucleotide sequence and is complementary to a region lying between a nucleotide located at position-13520 to a nucleotide located at position-13550 in SARS-CoV-2 RNA genome comprising the nucleotide sequence represented by SEQ ID NO: 1; and the oligonucleotide is a mixmer and is capable of inhibiting the viral proliferation of coronaviruses, wherein the 5'-end and / or the 3'-end of the oligonucleotide may be chemically modified. Also provided is a drug comprising the oligonucleotide or a pharmaceutically acceptable salt thereof.

This invention discloses the preparation and application of a universal mRNA vaccine for H5N1 influenza. The mRNA vaccine contains mRNA molecule 1 and mRNA molecule 2; mRNA molecule 1 encodes the H5m protein; mRNA molecule 2 encodes the N1m protein; the H5m protein is the protein shown in SEQ ID NO:1; the N1m protein is the protein shown in SEQ ID NO:2. The universal mRNA vaccine for H5N1 influenza prepared by this invention possesses broad-spectrum protection, rapid iteration, and low-cost mass production characteristics. It can efficiently express native conformational proteins in host cells, not only covering the main variation spectrum of the H5N1 virus, but also overcoming the broad-spectrum limitations of traditional vaccines by activating cross-neutralizing antibodies and polyclonal T-cell immunity. This invention provides key technical support for addressing the continuous evolution and potential pandemic of H5N1.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-COV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

The method describes an invention whose novelty also rests on activating the high existing capacity of individual citizens who are willing or legally obligated to perform a high level of effort in preventing their own infection over a short period of time. This is because asking citizens for help, supported by long-term measures, is not particularly effective because citizens primarily have a self-interest, not necessarily a public interest, and because testing measures in private settings is largely impossible. The inventive achievement is characterized, among other things, by the fact that, taking into account one- and two-stage testing procedures, an automatic mechanism is created to synchronize joint infection prevention during a pandemic. This allows for the longest possible phases in which infection prevention can be carried out with less stress, thus allowing normality to return to everyday life, and subsequently providing the motivation for a short phase of performance. Thus, the method is socially applicable for various infectious diseases, for pandemics, but also for other situations in which infection must be prevented, such as the consequences of the use of biological weapons.

Aspects of the present disclosure are directed to a Biological and Chemical Threat Prediction and Reasoning System (BiCEPS). BiCEPS can leverage Artificial Intelligence (AI) and Machine Learning (ML) approaches on uniquely pre-processed data derived from wearable devices to enable early detection, monitoring, and possibly prevention (or containment) of communicable diseases that can result in pandemics. Such communicable diseases may hereinafter be referred to as biological and / or chemical threats or simply threats.

The invention addresses the problem of air filtration and decontamination as required immediately for the COVID-19 pandemic but also will be useful in a variety of applications. Air (1) to the apparatus (100) enters and passes through an optional pre-filter (2) and through a one- way air "check" valve (3). The incoming air (1) then enters the counter-flow heat exchange path (4) and proceeds towards the heating chamber (6). As air enters the heating chamber (6), it immediately encounters heating elements (7). Upon encountering the heating chamber (6), the incoming air, which has been pre-heated by the exiting air, is heated to the desired temperature and exits via the return path (5). Upon completing the path through the exit path for the air, the air is now cooled to the desired exit temperature, for example within a few degrees of the incoming air, and is at a temperature suitable to exit (11) and be delivered to a user. This air may not have the virus removed from it, but the virus will be rendered harmless at this point. The invention is applicable in other contexts. For example, the operation of these systems can generally be reversed to decontaminate air including air exhaled by a user. This may be used in conjunction with a mask worn by a patient or an isolation chamber at least partially enclosing a patient, e.g., a patient room(s) or a tent erected over a patient gurney or bed.

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The viral genome is 26-32 kilobases in length. In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, reliable diagnostic methods are highly desirable. In particular, the development and availability of tests for the detection and quantification of anti-SARS-CoV-2 antibodies in subjects with COVID-19 is of strong diagnostic interest. The present fulfils this need. In particular, the inventors developed an Adressable Laser Beads ImmunoAssay (ALBIA) method based on the use of particles conjugated with a coronaviral polypeptides (S1,S2, S2', N, PL-Pro). More particularly, the inventors show that detection and titration of anti-SARS-Cov-2 Spike S1 IgG and IgM antibodies are feasible by said method.

A composition includes a first primer set consisting of the nucleotide sequences of SEQ ID Nos.1 to 6, and a second primer set consisting of the nucleotide sequences of SEQ ID Nos. 7 to 11. A multi-diagnostic kit for mosquito-borne diseases includes the composition. The multi-diagnostic kit enables rapid and accurate detection of dengue virus and malaria parasites by using specific primer sets. The multi-diagnostic kit is applicable in regions with high incidences of mosquito-borne disease pandemics including Africa and Latin America since it exhibits excellent thermal stability even in harsh environments.

Angiotensin-converting enzyme 2(ACE2) has been confirmed as a specific receptor for several β group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.

A method of assessing and analysing closely mimicking or overlapping patient clinical characteristics, presentations, manifestations and conditions that often appear confusing to treating physicians and medical / clinical experts, and pose concerns for true diagnostic detection of the actual underlying disease, is described and presented in here which utilizes Artificial Intelligence-based approach that requires less manual involvement and will drastically reduce diagnostic turnaround time thereby proving effective and beneficial for starting appropriate treatments quickly during unprecedented times like a pandemic when fatal fear of novel disease spread limits in-person physical examination of the affected as well as to be deployed during regular medical practices / emergencies amidst global or regional lockdowns and in other related / relatable fields.